Wall Street Zen cut shares of Cingulate (NASDAQ:CING – Free Report) from a sell rating to a strong sell rating in a report released on Saturday morning,Wall Street Zen reports.
A number of other research analysts also recently weighed in on CING. Weiss Ratings downgraded Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. Roth Capital set a $9.00 target price on Cingulate and gave the company a “buy” rating in a research note on Sunday, August 23rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.00.
Get Our Latest Analysis on Cingulate
Cingulate Trading Down 14.3%
NASDAQ:CING opened at $4.51 on Friday. The company has a 50-day moving average price of $4.81 and a 200-day moving average price of $5.36. Cingulate has a 12 month low of $3.16 and a 12 month high of $11.89. The stock has a market cap of $67.47 million, a price-to-earnings ratio of -1.63 and a beta of -0.88.
Cingulate (NASDAQ:CING – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). Equities analysts forecast that Cingulate will post -2.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Cingulate
Hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Cingulate during the second quarter valued at approximately $291,000. Renaissance Technologies LLC bought a new stake in shares of Cingulate in the 1st quarter worth approximately $198,000. Finally, Kestra Advisory Services LLC boosted its position in shares of Cingulate by 14.8% in the 1st quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock worth $869,000 after purchasing an additional 18,000 shares in the last quarter. Institutional investors own 41.31% of the company’s stock.
About Cingulate
Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day. Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD. The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates.
Further Reading
- Five stocks we like better than Cingulate
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
